Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients
The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory ou...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2021-12, Vol.93 (12), p.6557-6565 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6565 |
|---|---|
| container_issue | 12 |
| container_start_page | 6557 |
| container_title | Journal of medical virology |
| container_volume | 93 |
| creator | Kalantari, Saeed Fard, Soheil R. Maleki, Donya Taher, Mahshid T. Yassin, Zeynab Alimohamadi, Yousef Minaeian, Sara |
| description | The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory outcomes of 62 moderate to severe COVID‐19 patients during a 10‐day treatment plan. Patients were randomly assigned to either KH (receiving Lopinavir/Ritonavir [Kaletra] plus Hydroxychloroquine) or ADH (receiving Atazanavir/Ritonavir, Dolutegravir, and Hydroxychloroquine) groups. During this period, clinical and laboratory parameters and outcomes such as intensive care unit (ICU) admission or mortality rate were recorded. Compared to the KH group, after the treatment period, patients in the ADH group had higher activated partial thromboplastin time (aPTT) (12, [95% confidence interval [CI]: 6.97, 17.06), p = |
| doi_str_mv | 10.1002/jmv.27195 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8426706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2581298082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4485-a7ec3ea329da353d74e1c44131f56f6e1db93a9190d7a656648b183dda06bc9c3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS1ERYfCgjewxIYu0vFP4sQbpGoKtNWgSgi6tTzJzYxHiR1sZ2BY8Qg8Bs_Fk-BpKiQqWPla57vn-vog9IKSM0oIm2_73RkrqSweoRklUmSSlPQxmhGai0wIWhyjpyFsCSGVZOwJOuY5Kwou5Az9XLh-0N7YNY4bwNC2UEezAwshYNfi86i_aat3xs8_mOim6sJ1Y4S1v7tc7hvvvu7rTee8-zwaC1jbBi_dYB72_QONHnTswUbsYW1SEbCxeHFze3Xx6_sPKvGgo0lyeIaOWt0FeH5_nqBPb998XFxmy5t3V4vzZVbneVVkuoSag-ZMNpoXvClzoEmhnLaFaAXQZiW5llSSptSiECKvVrTiTaOJWNWy5ifo9eQ7jKsemjrN9rpTgze99nvltFF_K9Zs1NrtVJUzURKRDF7dGxx2hBBVb0INXactuDGo9POUUUJLltCXD9CtG71N6yWqokxWpDpQpxNVexeCh_bPYyhRh_xVyl_d5Z_Y-cR-MR3s_w-q6_e3U8dvQ5W3Mg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2581298082</pqid></control><display><type>article</type><title>Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kalantari, Saeed ; Fard, Soheil R. ; Maleki, Donya ; Taher, Mahshid T. ; Yassin, Zeynab ; Alimohamadi, Yousef ; Minaeian, Sara</creator><creatorcontrib>Kalantari, Saeed ; Fard, Soheil R. ; Maleki, Donya ; Taher, Mahshid T. ; Yassin, Zeynab ; Alimohamadi, Yousef ; Minaeian, Sara</creatorcontrib><description>The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory outcomes of 62 moderate to severe COVID‐19 patients during a 10‐day treatment plan. Patients were randomly assigned to either KH (receiving Lopinavir/Ritonavir [Kaletra] plus Hydroxychloroquine) or ADH (receiving Atazanavir/Ritonavir, Dolutegravir, and Hydroxychloroquine) groups. During this period, clinical and laboratory parameters and outcomes such as intensive care unit (ICU) admission or mortality rate were recorded. Compared to the KH group, after the treatment period, patients in the ADH group had higher activated partial thromboplastin time (aPTT) (12, [95% confidence interval [CI]: 6.97, 17.06), p = <0.01), international normalized ratio (INR) (0.17, [95% CI: 0.07, 0.27), p = <0.01) and lower C‐reactive protein (CRP) (−14.29, (95% CI: −26.87, −1.71), p = 0.03) and potassium (−0.53, (95% CI: −1.03, −0.03), p = 0.04) values. Moreover, a higher number of patients in the KH group needed invasive ventilation (6 (20%) vs. 1 (3.1%), p = 0.05) and antibiotic administration (27 (90%) vs. 21(65.6), p = 0.02) during hospitalization while patients in the ADH group needed more corticosteroid administration (9 (28.1%) vs. 2 (6.7%), p = 0.03). There was no difference in mortality rate, ICU admission rate, and hospitalization period between the study groups. Our results suggest that the Atazanavir/Dolutegravir treatment regimen may result in a less severe disease course compared to the Lopinavir/Ritonavir treatment regimen and can be considered as an alternative treatment option beside standard care. However, to confirm our results, larger‐scale studies are recommended.
Highlights
Despite the use of many drugs and efforts in controlling the COVID‐19 pandemic, no definitive cure has been found yet.
We compared the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in hospitalized COVID‐19 patients.
Clinical and laboratory results show that Atazanavir/Dolutegravir regimen is more effective in ameliorating the severity of COVID‐19 and may be a useful addition to treatment options for COVID‐19 alongside standard care.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.27195</identifier><identifier>PMID: 34255369</identifier><language>eng</language><publisher>London: Wiley Subscription Services, Inc</publisher><subject>Antibiotics ; Antiretroviral drugs ; Antiviral drugs ; Atazanavir ; Confidence intervals ; Corticosteroids ; COVID-19 ; Dolutegravir ; Health services ; Hydroxychloroquine ; Laboratories ; Lopinavir ; Mortality ; Pandemics ; Parameters ; Patients ; Potassium ; Potassium hydrides ; Ritonavir ; Thromboplastin ; Virology</subject><ispartof>Journal of medical virology, 2021-12, Vol.93 (12), p.6557-6565</ispartof><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4485-a7ec3ea329da353d74e1c44131f56f6e1db93a9190d7a656648b183dda06bc9c3</citedby><cites>FETCH-LOGICAL-c4485-a7ec3ea329da353d74e1c44131f56f6e1db93a9190d7a656648b183dda06bc9c3</cites><orcidid>0000-0002-3133-7859 ; 0000-0002-8787-5971 ; 0000-0002-4480-9827 ; 0000-0002-9731-5345 ; 0000-0001-9896-4139 ; 0000-0002-1915-6596 ; 0000-0002-1252-8035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.27195$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.27195$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Kalantari, Saeed</creatorcontrib><creatorcontrib>Fard, Soheil R.</creatorcontrib><creatorcontrib>Maleki, Donya</creatorcontrib><creatorcontrib>Taher, Mahshid T.</creatorcontrib><creatorcontrib>Yassin, Zeynab</creatorcontrib><creatorcontrib>Alimohamadi, Yousef</creatorcontrib><creatorcontrib>Minaeian, Sara</creatorcontrib><title>Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients</title><title>Journal of medical virology</title><description>The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory outcomes of 62 moderate to severe COVID‐19 patients during a 10‐day treatment plan. Patients were randomly assigned to either KH (receiving Lopinavir/Ritonavir [Kaletra] plus Hydroxychloroquine) or ADH (receiving Atazanavir/Ritonavir, Dolutegravir, and Hydroxychloroquine) groups. During this period, clinical and laboratory parameters and outcomes such as intensive care unit (ICU) admission or mortality rate were recorded. Compared to the KH group, after the treatment period, patients in the ADH group had higher activated partial thromboplastin time (aPTT) (12, [95% confidence interval [CI]: 6.97, 17.06), p = <0.01), international normalized ratio (INR) (0.17, [95% CI: 0.07, 0.27), p = <0.01) and lower C‐reactive protein (CRP) (−14.29, (95% CI: −26.87, −1.71), p = 0.03) and potassium (−0.53, (95% CI: −1.03, −0.03), p = 0.04) values. Moreover, a higher number of patients in the KH group needed invasive ventilation (6 (20%) vs. 1 (3.1%), p = 0.05) and antibiotic administration (27 (90%) vs. 21(65.6), p = 0.02) during hospitalization while patients in the ADH group needed more corticosteroid administration (9 (28.1%) vs. 2 (6.7%), p = 0.03). There was no difference in mortality rate, ICU admission rate, and hospitalization period between the study groups. Our results suggest that the Atazanavir/Dolutegravir treatment regimen may result in a less severe disease course compared to the Lopinavir/Ritonavir treatment regimen and can be considered as an alternative treatment option beside standard care. However, to confirm our results, larger‐scale studies are recommended.
Highlights
Despite the use of many drugs and efforts in controlling the COVID‐19 pandemic, no definitive cure has been found yet.
We compared the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in hospitalized COVID‐19 patients.
Clinical and laboratory results show that Atazanavir/Dolutegravir regimen is more effective in ameliorating the severity of COVID‐19 and may be a useful addition to treatment options for COVID‐19 alongside standard care.</description><subject>Antibiotics</subject><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Atazanavir</subject><subject>Confidence intervals</subject><subject>Corticosteroids</subject><subject>COVID-19</subject><subject>Dolutegravir</subject><subject>Health services</subject><subject>Hydroxychloroquine</subject><subject>Laboratories</subject><subject>Lopinavir</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Parameters</subject><subject>Patients</subject><subject>Potassium</subject><subject>Potassium hydrides</subject><subject>Ritonavir</subject><subject>Thromboplastin</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAUhS1ERYfCgjewxIYu0vFP4sQbpGoKtNWgSgi6tTzJzYxHiR1sZ2BY8Qg8Bs_Fk-BpKiQqWPla57vn-vog9IKSM0oIm2_73RkrqSweoRklUmSSlPQxmhGai0wIWhyjpyFsCSGVZOwJOuY5Kwou5Az9XLh-0N7YNY4bwNC2UEezAwshYNfi86i_aat3xs8_mOim6sJ1Y4S1v7tc7hvvvu7rTee8-zwaC1jbBi_dYB72_QONHnTswUbsYW1SEbCxeHFze3Xx6_sPKvGgo0lyeIaOWt0FeH5_nqBPb998XFxmy5t3V4vzZVbneVVkuoSag-ZMNpoXvClzoEmhnLaFaAXQZiW5llSSptSiECKvVrTiTaOJWNWy5ifo9eQ7jKsemjrN9rpTgze99nvltFF_K9Zs1NrtVJUzURKRDF7dGxx2hBBVb0INXactuDGo9POUUUJLltCXD9CtG71N6yWqokxWpDpQpxNVexeCh_bPYyhRh_xVyl_d5Z_Y-cR-MR3s_w-q6_e3U8dvQ5W3Mg</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Kalantari, Saeed</creator><creator>Fard, Soheil R.</creator><creator>Maleki, Donya</creator><creator>Taher, Mahshid T.</creator><creator>Yassin, Zeynab</creator><creator>Alimohamadi, Yousef</creator><creator>Minaeian, Sara</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3133-7859</orcidid><orcidid>https://orcid.org/0000-0002-8787-5971</orcidid><orcidid>https://orcid.org/0000-0002-4480-9827</orcidid><orcidid>https://orcid.org/0000-0002-9731-5345</orcidid><orcidid>https://orcid.org/0000-0001-9896-4139</orcidid><orcidid>https://orcid.org/0000-0002-1915-6596</orcidid><orcidid>https://orcid.org/0000-0002-1252-8035</orcidid></search><sort><creationdate>202112</creationdate><title>Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients</title><author>Kalantari, Saeed ; Fard, Soheil R. ; Maleki, Donya ; Taher, Mahshid T. ; Yassin, Zeynab ; Alimohamadi, Yousef ; Minaeian, Sara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4485-a7ec3ea329da353d74e1c44131f56f6e1db93a9190d7a656648b183dda06bc9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Atazanavir</topic><topic>Confidence intervals</topic><topic>Corticosteroids</topic><topic>COVID-19</topic><topic>Dolutegravir</topic><topic>Health services</topic><topic>Hydroxychloroquine</topic><topic>Laboratories</topic><topic>Lopinavir</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Parameters</topic><topic>Patients</topic><topic>Potassium</topic><topic>Potassium hydrides</topic><topic>Ritonavir</topic><topic>Thromboplastin</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalantari, Saeed</creatorcontrib><creatorcontrib>Fard, Soheil R.</creatorcontrib><creatorcontrib>Maleki, Donya</creatorcontrib><creatorcontrib>Taher, Mahshid T.</creatorcontrib><creatorcontrib>Yassin, Zeynab</creatorcontrib><creatorcontrib>Alimohamadi, Yousef</creatorcontrib><creatorcontrib>Minaeian, Sara</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalantari, Saeed</au><au>Fard, Soheil R.</au><au>Maleki, Donya</au><au>Taher, Mahshid T.</au><au>Yassin, Zeynab</au><au>Alimohamadi, Yousef</au><au>Minaeian, Sara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients</atitle><jtitle>Journal of medical virology</jtitle><date>2021-12</date><risdate>2021</risdate><volume>93</volume><issue>12</issue><spage>6557</spage><epage>6565</epage><pages>6557-6565</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>The purpose of this study was to compare the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients based on clinical and laboratory parameters. We prospectively evaluated the clinical and laboratory outcomes of 62 moderate to severe COVID‐19 patients during a 10‐day treatment plan. Patients were randomly assigned to either KH (receiving Lopinavir/Ritonavir [Kaletra] plus Hydroxychloroquine) or ADH (receiving Atazanavir/Ritonavir, Dolutegravir, and Hydroxychloroquine) groups. During this period, clinical and laboratory parameters and outcomes such as intensive care unit (ICU) admission or mortality rate were recorded. Compared to the KH group, after the treatment period, patients in the ADH group had higher activated partial thromboplastin time (aPTT) (12, [95% confidence interval [CI]: 6.97, 17.06), p = <0.01), international normalized ratio (INR) (0.17, [95% CI: 0.07, 0.27), p = <0.01) and lower C‐reactive protein (CRP) (−14.29, (95% CI: −26.87, −1.71), p = 0.03) and potassium (−0.53, (95% CI: −1.03, −0.03), p = 0.04) values. Moreover, a higher number of patients in the KH group needed invasive ventilation (6 (20%) vs. 1 (3.1%), p = 0.05) and antibiotic administration (27 (90%) vs. 21(65.6), p = 0.02) during hospitalization while patients in the ADH group needed more corticosteroid administration (9 (28.1%) vs. 2 (6.7%), p = 0.03). There was no difference in mortality rate, ICU admission rate, and hospitalization period between the study groups. Our results suggest that the Atazanavir/Dolutegravir treatment regimen may result in a less severe disease course compared to the Lopinavir/Ritonavir treatment regimen and can be considered as an alternative treatment option beside standard care. However, to confirm our results, larger‐scale studies are recommended.
Highlights
Despite the use of many drugs and efforts in controlling the COVID‐19 pandemic, no definitive cure has been found yet.
We compared the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in hospitalized COVID‐19 patients.
Clinical and laboratory results show that Atazanavir/Dolutegravir regimen is more effective in ameliorating the severity of COVID‐19 and may be a useful addition to treatment options for COVID‐19 alongside standard care.</abstract><cop>London</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34255369</pmid><doi>10.1002/jmv.27195</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3133-7859</orcidid><orcidid>https://orcid.org/0000-0002-8787-5971</orcidid><orcidid>https://orcid.org/0000-0002-4480-9827</orcidid><orcidid>https://orcid.org/0000-0002-9731-5345</orcidid><orcidid>https://orcid.org/0000-0001-9896-4139</orcidid><orcidid>https://orcid.org/0000-0002-1915-6596</orcidid><orcidid>https://orcid.org/0000-0002-1252-8035</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2021-12, Vol.93 (12), p.6557-6565 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8426706 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antibiotics Antiretroviral drugs Antiviral drugs Atazanavir Confidence intervals Corticosteroids COVID-19 Dolutegravir Health services Hydroxychloroquine Laboratories Lopinavir Mortality Pandemics Parameters Patients Potassium Potassium hydrides Ritonavir Thromboplastin Virology |
| title | Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A33%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparing%20the%20effectiveness%20of%20Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine%20and%20Lopinavir/Ritonavir/Hydroxychloroquine%20treatment%20regimens%20in%20COVID%E2%80%9019%20patients&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Kalantari,%20Saeed&rft.date=2021-12&rft.volume=93&rft.issue=12&rft.spage=6557&rft.epage=6565&rft.pages=6557-6565&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.27195&rft_dat=%3Cproquest_pubme%3E2581298082%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2581298082&rft_id=info:pmid/34255369&rfr_iscdi=true |